HRP960507B1 - 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives - Google Patents

1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives

Info

Publication number
HRP960507B1
HRP960507B1 HR960507A HRP960507A HRP960507B1 HR P960507 B1 HRP960507 B1 HR P960507B1 HR 960507 A HR960507 A HR 960507A HR P960507 A HRP960507 A HR P960507A HR P960507 B1 HRP960507 B1 HR P960507B1
Authority
HR
Croatia
Prior art keywords
piperazine derivatives
substituted piperazine
disubstituted piperidinyl
disubstituted
piperidinyl
Prior art date
Application number
HR960507A
Other languages
English (en)
Inventor
Frans Eduard Janssens
Francois Maria Sommen
Dominique Louis Mesto Surleaux
Joseph Elisabeth Leenaerts
Roosbroeck Yves Emiel Mari Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8220780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP960507(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HRP960507A2 publication Critical patent/HRP960507A2/hr
Publication of HRP960507B1 publication Critical patent/HRP960507B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
HR960507A 1995-10-30 1996-10-30 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives HRP960507B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95202929 1995-10-30

Publications (2)

Publication Number Publication Date
HRP960507A2 HRP960507A2 (en) 1998-02-28
HRP960507B1 true HRP960507B1 (en) 2001-08-31

Family

ID=8220780

Family Applications (1)

Application Number Title Priority Date Filing Date
HR960507A HRP960507B1 (en) 1995-10-30 1996-10-30 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives

Country Status (31)

Country Link
US (3) US6197772B1 (zh)
EP (1) EP0862566B1 (zh)
JP (1) JP3073238B2 (zh)
KR (1) KR100407067B1 (zh)
CN (2) CN1117744C (zh)
AR (1) AR004698A1 (zh)
AT (1) ATE188691T1 (zh)
AU (1) AU704155B2 (zh)
BR (1) BR9611184B8 (zh)
CA (1) CA2234096C (zh)
CY (1) CY2177B1 (zh)
CZ (1) CZ291794B6 (zh)
DE (1) DE69606196T2 (zh)
DK (1) DK0862566T3 (zh)
EA (1) EA000909B1 (zh)
ES (1) ES2143238T3 (zh)
GR (1) GR3033154T3 (zh)
HR (1) HRP960507B1 (zh)
HU (1) HU227341B1 (zh)
IL (1) IL123962A (zh)
MX (1) MX9803407A (zh)
MY (1) MY116575A (zh)
NO (1) NO310232B1 (zh)
NZ (1) NZ321575A (zh)
PL (1) PL185029B1 (zh)
PT (1) PT862566E (zh)
SI (1) SI0862566T1 (zh)
TR (1) TR199800756T2 (zh)
TW (1) TW460473B (zh)
WO (1) WO1997016440A1 (zh)
ZA (1) ZA969090B (zh)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ321575A (en) * 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW382017B (en) 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
TW429256B (en) * 1995-12-27 2001-04-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
WO1999032486A1 (en) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
US6391865B1 (en) 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
US6689765B2 (en) 1999-05-04 2004-02-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
WO2001030348A1 (en) * 1999-10-25 2001-05-03 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
PL364560A1 (en) 2001-03-29 2004-12-13 Schering Corporation Ccr5 antagonists useful for treating aids
GB0108594D0 (en) * 2001-04-05 2001-05-23 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
JP2005522436A (ja) * 2002-02-08 2005-07-28 グラクソ　グループ　リミテッド ピペリジルカルボキシアミド誘導体またはそのタキキニン介在疾患の治療における使用
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
ES2326800T3 (es) 2002-06-24 2009-10-20 Janssen Pharmaceutica Nv Proceso para la produccion de n-(2,6-dimetil-fenil)-2-piperazin-1-il-acetamida.
MY141736A (en) * 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists
WO2004056772A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use as tachykinin antagonists
CA2501539A1 (en) * 2002-10-17 2004-04-29 Amgen Inc. Benzimidazole derivatives and their use as vanilloid receptor ligands
US7514424B2 (en) 2002-12-23 2009-04-07 Janssen Pharmaceutica N.V. Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists
WO2004056800A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
JO2485B1 (en) * 2002-12-23 2009-01-20 شركة جانسين فارماسوتيكا ان. في 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
ES2307025T3 (es) * 2003-06-10 2008-11-16 Janssen Pharmaceutica Nv Combinacion de opioides y un derivado de la piperazina para el tratamiento del dolor.
WO2004110415A2 (en) * 2003-06-10 2004-12-23 Janssen Pharmaceutica N.V. Substituted 1, 4-di-piperidin-4-yl-piperazine derivative combined with an opioid analgesic and their use for the treatment of pain and side-effects associated with opioid-based treatments
UY28538A1 (es) * 2003-09-26 2005-04-29 Vertex Pharma Derivados de fenil-piperazina como moduladores de receptores muscarínicos
JO2527B1 (en) * 2004-04-06 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derivatives of second-aza-Spiro- (5,5) -andecan and their use as antihistamines
JO2676B1 (en) * 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
JO2525B1 (en) * 2004-04-08 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin
EP1734966B1 (en) 2004-04-13 2013-07-31 Incyte Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
WO2005123081A2 (en) * 2004-06-22 2005-12-29 Janssen Pharmaceutica N.V. (2-benzyl-4-{4-[1-(tetrahydrofuran-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-trifluoromethyl-phenyl))-methanone for the treatment of schizophrenia
US20060024481A1 (en) * 2004-07-29 2006-02-02 Eastman Kodak Company Jet printing of patterned metal
CA2576166C (en) 2004-08-19 2018-02-20 Monsanto Technology Llc Glyphosate salt herbicidal composition
WO2006071958A1 (en) * 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
ATE478075T1 (de) 2005-03-08 2010-09-15 Janssen Pharmaceutica Nv Diazaspiro-ä4,4ü-nonanderivate als neurokinin- (nk1)-antagonisten
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
EA200970706A1 (ru) 2007-01-24 2010-02-26 Глэксо Груп Лимитед Новые фармацевтические композиции
WO2010081851A1 (en) 2009-01-14 2010-07-22 Genoscience Pharma Piperidin-4-ylpiperazine compounds for the treatment of hcv infection
CN101913076B (zh) * 2010-06-23 2012-09-05 中国科学院自动化研究所 基于工业机器人的活塞、活塞销和连杆装配方法及装置
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
PT2956440T (pt) 2013-02-08 2018-05-08 Gen Mills Inc Produtos alimentares com baixo teor de sódio
SI3083616T1 (sl) 2013-12-20 2021-12-31 Astex Therapeutics Limited Biciklične heterociklične spojine in njihova uporaba pri zdravljenju
DK3377064T3 (da) * 2016-01-08 2019-09-23 Nerre Therapeutics Ltd Orvepitant til behandling af kronisk hoste

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
CN1042335C (zh) * 1993-01-03 1999-03-03 诺瓦提斯公司 1－酰基哌啶化合物、其制备方法、药物组合物及用途
ES2105003T3 (es) * 1993-05-12 1997-10-16 Heumann Pharma Gmbh & Co Forma estable y cristalina del bezafibrato.
GB9310066D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Alkyl substituted heterocycles
WO1995011895A1 (en) * 1993-10-26 1995-05-04 Ciba-Geigy Ag N-benzoyl-4-oxy/thio-2-substituted piperidines as substance-p receptor antagonists
IL111730A (en) * 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them
CA2171850A1 (en) * 1994-07-15 1996-02-01 Kiyoaki Katano Novel compound having platelet aggregation inhibitor effect
EP0783490B1 (en) * 1994-09-30 2002-02-06 Novartis AG 1-acyl-4-aliphatic aminopiperidine compounds
NZ321575A (en) * 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives

Also Published As

Publication number Publication date
JP3073238B2 (ja) 2000-08-07
TR199800756T2 (xx) 1998-07-21
ES2143238T3 (es) 2000-05-01
PL185029B1 (pl) 2003-02-28
NO981534D0 (no) 1998-04-03
ATE188691T1 (de) 2000-01-15
US6197772B1 (en) 2001-03-06
SI0862566T1 (en) 2000-04-30
AU7493296A (en) 1997-05-22
BR9611184B8 (pt) 2015-02-18
MX9803407A (es) 1998-09-30
CZ132298A3 (cs) 1998-09-16
DE69606196D1 (de) 2000-02-17
EA199800404A1 (ru) 1998-10-29
ZA969090B (en) 1998-04-29
CN1438220A (zh) 2003-08-27
NO981534L (no) 1998-06-24
PL327406A1 (en) 1998-12-07
DK0862566T3 (da) 2000-06-13
US6521621B1 (en) 2003-02-18
DE69606196T2 (de) 2000-09-21
CN1117744C (zh) 2003-08-13
TW460473B (en) 2001-10-21
AR004698A1 (es) 1999-03-10
PT862566E (pt) 2000-06-30
HU227341B1 (en) 2011-04-28
KR100407067B1 (ko) 2004-06-04
MY116575A (en) 2004-02-28
EP0862566B1 (en) 2000-01-12
HUP9802985A2 (hu) 1999-10-28
GR3033154T3 (en) 2000-08-31
USRE37886E1 (en) 2002-10-15
WO1997016440A1 (en) 1997-05-09
HRP960507A2 (en) 1998-02-28
JPH11514634A (ja) 1999-12-14
CA2234096C (en) 2005-06-14
CZ291794B6 (cs) 2003-05-14
EP0862566A1 (en) 1998-09-09
CY2177B1 (en) 2002-08-23
IL123962A (en) 2001-01-11
CN1205699A (zh) 1999-01-20
CA2234096A1 (en) 1997-05-09
CN100415716C (zh) 2008-09-03
NO310232B1 (no) 2001-06-11
HUP9802985A3 (en) 2002-10-28
NZ321575A (en) 1999-05-28
EA000909B1 (ru) 2000-06-26
KR19990064178A (ko) 1999-07-26
BR9611184A (pt) 1999-03-30
AU704155B2 (en) 1999-04-15

Similar Documents

Publication Publication Date Title
GR3033154T3 (en) 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives
CZ186498A3 (cs) 1-(1,2-Disubstituovaný piperidinyl)-4-substituované deriváty piperidinu
ZA964101B (en) Piperazine derivatives
IL124641A0 (en) 1-(1,2-Disubstituted piperidinyl)-4- (fused imidazole)- piperidine derivatives
HU9301553D0 (en) 1-(3,4-disubstituted phenyl)-tetrazolinone derivatives
ZA952431B (en) New piperidine derivatives
GB9514901D0 (en) Piperazine derivatives
ZA948520B (en) 1-[2H-1-benzopyran-2one-8-yl]-piperazine derivatives
AU2793197A (en) 1,4-disubstituted piperidine derivatives
ZA96702B (en) 4-(1H-indol-1-yl)-1-piperidinyl derivatives.
GB9510600D0 (en) Piperazine derivatives
ZA9610894B (en) 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives.
ZA943036B (en) 1,4-disubstituted piperidine derivative compounds
ZA944720B (en) 2-[1-(1,3-thiazolin-2-yl) azetidin-3-yl] thio-carbapenem derivatives
ZA959170B (en) Benzylpiperidine derivatives
SI0853619T1 (en) Disubstituted piperidine derivatives
ZA9610428B (en) Piperazine derivatives
SI0765311T1 (en) 4-aryl-1-(indanmethyl, dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl)piperidines, tetrahydropyridines or piperazines
IL126564A (en) 1-(1-Oxoindan-2-yl) imidazole-2-carboxylate derivatives

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20150904

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20161030